Primed Stem Cells for Joint Inflammation via Cytokine Conditioning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for joint inflammation, such as those caused by degenerative joint disease, are not as safe and effective as desired, and there is a need for new approaches to control inflammation and promote tissue regeneration in synovial joints.
Innovation Solution
The method involves isolating and expanding stem or progenitor cells, exposing them to conditions mimicking the inflammatory environment of a synovial joint to 'prime' them for enhanced anti-inflammatory effects, and administering these primed cells directly to the inflamed joint, either as a standalone treatment or during surgery, often in combination with a pharmaceutically acceptable carrier that may include growth factors and natural joint fluid components.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatments are used for joint inflammation, then inflammation control is achieved, but safety and effectiveness are insufficient
Solution Approach 1:
The patent applies preliminary action by pre-conditioning stem cells in vitro with inflammatory cytokines (IL-1β, TNF-α) before administration. This pre-exposure primes the cells to produce anti-inflammatory factors (IL-10, TGF-β) when introduced into the joint, making them more effective than unconditioned cells while reducing the need for high doses of potentially harmful anti-inflammatory drugs.
2Reliability
If stem cells are administered without priming, then treatment is simpler, but anti-inflammatory effects are insufficient
Solution Approach 1:
The patent implements preliminary action through an in vitro conditioning step where stem cells are exposed to inflammatory cytokines before transplantation. This pre-treatment enhances the cells' therapeutic capacity to reduce inflammation in vivo, addressing the insufficiency of unprimed cells without requiring complex in vivo manipulation procedures.
Solution Approach 2:
The patent uses inflammatory cytokines (IL-1β, TNF-α) as intermediaries during the in vitro conditioning phase. These cytokines act as mediators to trigger the stem cells' anti-inflammatory response, which is then transferred to the joint environment. The cytokines serve as a bridge between the simple cell administration and the complex anti-inflammatory effect desired.
3Reliability
If stem cells are exposed to inflammatory conditions in culture, then anti-inflammatory effects are enhanced, but culture conditions become more complex
Solution Approach 1:
The patent applies parameter changes by modifying the culture medium composition to include specific inflammatory cytokines (IL-1β, TNF-α) at defined concentrations. This controlled alteration of cultural parameters transforms the stem cells' phenotype, enhancing their anti-inflammatory capacity without requiring complex physical or chemical modifications to the culture system.
Data Source
AI summary
Disclosed are methods of treating inflammation within a synovial joint, comprising administering to the joint a composition comprising primed stem or progenitor cells in an amount effective to enhance recovery, and a pharmaceutically acceptable carrier.